WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and fourteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $27.25.
Several equities analysts recently weighed in on WVE shares. Wall Street Zen upgraded shares of WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a report on Saturday, May 2nd. Bank of America cut their price objective on shares of WAVE Life Sciences from $38.00 to $21.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Wedbush upped their target price on shares of WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Cantor Fitzgerald upped their target price on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Mizuho upped their target price on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th.
View Our Latest Analysis on WAVE Life Sciences
Institutional Investors Weigh In On WAVE Life Sciences
WAVE Life Sciences Price Performance
Shares of NASDAQ WVE opened at $6.58 on Wednesday. The company’s 50 day simple moving average is $7.45 and its 200 day simple moving average is $11.08. WAVE Life Sciences has a fifty-two week low of $5.02 and a fifty-two week high of $21.73. The firm has a market capitalization of $1.27 billion, a P/E ratio of -6.21 and a beta of -1.32.
WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.21. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $8.45 million. Sell-side analysts expect that WAVE Life Sciences will post -1.16 EPS for the current fiscal year.
About WAVE Life Sciences
WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.
The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.
Featured Articles
- Five stocks we like better than WAVE Life Sciences
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
